about
Universal and reusable virus deactivation system for respiratory protectionThe osmotic stress response of split influenza vaccine particles in an acidic environment.Smart Microparticles with a pH-responsive Macropore for Targeted Oral Drug Delivery.Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection.Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responsesRecent Progress in Advanced Nanobiological Materials for Energy and Environmental ApplicationsRespiratory Protection against Pandemic and Epidemic Diseases.Microfabrication for Drug DeliverypH stability and comparative evaluation of ranaspumin-2 foam for application in biochemical reactors.Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.Antioxidant-based synergistic eradication of methicillin-resistant Staphylococcus aureus (MRSA) biofilms with bacitracin.Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation.Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza VirusChallenges and Recent Progress in Oral Drug Delivery Systems for BiopharmaceuticalsCo-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection.Macropored microparticles with a core-shell architecture for oral delivery of biopharmaceuticalsInfluenza Virus-Like Particles Presenting both Toxoplasma gondii ROP4 and ROP13 Enhance Protection against T. gondii Infection
P50
Q28359554-A74F6BB3-EBA6-4ED3-BB46-B7EABFB56AEAQ30354213-3DA93C8E-A4CE-447C-BA4B-5A798106C9BCQ30855198-C7A1E598-F822-400B-891B-C91175213F9CQ33562716-81E64A5F-2473-40CE-8C87-E5470D32C2CCQ35731299-A0500FAF-2335-420E-9373-D5101F0460BFQ35811003-5DD2487F-275B-4DD3-A805-3D0AC20AA0ACQ35883016-72C1AA38-F8E6-474A-B559-EE0351129536Q38633925-C221D035-F179-4299-9C24-3BB7A287C545Q40112921-2DAB5897-EB1B-449F-B98F-608BA484BD73Q41006286-F34995EB-A323-4A3D-A7CE-9C7ED6179939Q43723338-EDCAC2A5-49D9-4522-876C-3121750018F3Q45325239-AD1BF0AE-C10C-489D-B420-CE9485E92448Q47553049-83DCDF1F-A9FF-45DF-B5F7-AA14FF7540A4Q52642228-BB5A6C8D-9E55-46CB-B505-2FB556449222Q55399562-93E98EAF-9C74-43B6-B0C9-7ADE6CE639A1Q59352166-70B4ABD5-37B5-4B1B-AE8D-71AFB9EA6342Q64077456-6FF67228-20E3-4956-8674-E6CE33B0BAC5Q64929053-56935058-8FB2-44F0-8FD9-4DA8411B2736Q90863828-9145F8D3-FFF4-483E-A4D9-DAF27E9B124FQ91961967-7B5A8BF3-DF22-4BB1-B249-A43E910B0189
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hyo-Jick Choi
@ast
Hyo-Jick Choi
@en
Hyo-Jick Choi
@es
Hyo-Jick Choi
@nl
type
label
Hyo-Jick Choi
@ast
Hyo-Jick Choi
@en
Hyo-Jick Choi
@es
Hyo-Jick Choi
@nl
prefLabel
Hyo-Jick Choi
@ast
Hyo-Jick Choi
@en
Hyo-Jick Choi
@es
Hyo-Jick Choi
@nl
P106
P31
P496
0000-0001-8233-5864